
Compass Therapeutics, Inc.: updates and filings
Price
$0.69
November 20, 2026Market cap $124M
What Ploutos Investor adds for Compass Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 20, 2026Delisting noticeForm8-K
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Sep 22, 2026Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 1, 2026Regulation FD disclosureForm8-K
- Jun 23, 2026Amended articles or bylawsForm8-K
- Jun 11, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Apr 27, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 12, 2026Shares registered for employeesFormS-8
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 7, 2026FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 20, 2026 | 8-K | Delisting notice | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Sep 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 23, 2026 | 8-K | Amended articles or bylaws | Document |
| Jun 11, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 12, 2026 | S-8 | Shares registered for employees | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 7, 2026 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 30, 2018.
The full analysis
What do Compass Therapeutics's filings show?
The filings are where every one of Compass Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.